Form 4: Kiniksa Pharmaceuticals Executive Ross Moat Reports Share Transactions

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, reports acquisition and disposal of Class A Ordinary Shares and derivative securities.

Summary

• On April 1, 2025, Ross Moat, the Chief Commercial Officer of Kiniksa Pharmaceuticals International, plc, reported transactions involving Class A Ordinary Shares.
• Moat acquired 1,611 and 1,741 shares through the vesting of Restricted Share Units (RSUs).
• He also disposed of 473 and 511 shares to cover tax obligations at a price of $21.77 per share.
• Following these transactions, Moat directly owns 25,924 Class A Ordinary Shares.
• Moat also holds options for 39,364 shares, 9,828 Restricted Share Units, and 19,657 Performance Share Units.
• The share options vest over time, with 25% vesting on the first anniversary of April 1, 2025, and the remainder in equal monthly installments.
• RSUs vest over four years from the grant date of April 1, 2025.
• Performance Share Units (PSUs) can convert into up to 200% of one Class A Ordinary Share no later than January 30, 2028, based on performance criteria.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral. It simply reports transactions by an insider.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. It allows investors to monitor the actions of key executives and their alignment with company performance.

Stakeholder Impact

• Shareholders can monitor insider transactions for insights into management's perspective on the company's value.
• Employees holding similar equity grants may be interested in the vesting schedules and tax implications.

Key Dates

Keywords

Kiniksa Pharmaceuticals, Ross Moat, Class A Ordinary Shares, Restricted Share Units, Performance Share Units, Share Options, Form 4, SEC Filing, Insider Trading